Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: cyclicarx.com
Number of Employees: -
Year Founded: 2010
Total Amount Raised (CAD mm)†: 30.01
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Cyclica Inc., a neo-biotech company, engages in drug discovery focuses on CNS, oncology, and auto-immune diseases. It develops an AI-augmented drug discovery platform that drives programs across diverse protein classes. The company was incorporated in 2010 and is based in Toronto, Canada. Cyclica Therapeutics Inc operates as a subsidiary of Recursion Pharmaceuticals, Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Kurji, Naheed 
Co-Founder, CEO, President & Director
Shah, Pratik 
Chief Financial Officer
McQuarrie, Holly 
Manager of People & Operations
Palovich, Michael 
Chief Science Officer & Head of Drug Discovery
Gotlieb, Ted 
General Counsel
Sacco, Jennifer 
Vice President of Marketing & Communications
Climie, Shane 
Vice President of Corporate Development
De Biasi, Vern 
Chief Partnership Officer
MacKinnon, Stephen 
Chief Platform Officer
Windemuth, Andreas 
Chief Innovation Officer

Key Board Members
Name
Title
Analoui, Mostafa 
Chairman of the Board
Kurji, Naheed 
Co-Founder, CEO, President & Director
Bonakdarpour, Molly McCartin
Director
Chilukuri, Sastry 
Director
Conway, John F.
Scientific Advisor
List, Michael T. R.
Director
Panicucci, Riccardo 
Scientific Advisor
Prendergast, Franklyn G.
Scientific Advisor
Wodak, Shoshana 
Scientific Advisor


Primary Industry Classification
Health Care Technology


Primary Office Location
207 Queens Quay West Suite 420 | Toronto, ON | M5J 1A7 | Canada
Phone: 416-304-9201   

Parent Company
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX)

Prior Investors
Bayer G4A, Beijing Zhongguancun Dahe Capital Investment Management Co., Ltd., Chiesi Farmaceutici S.p.A., Drive Capital, LLC (Molly Bonakdarpour), Epic Capital Management, Inc., GreenSky Ventures, MaRs Discovery District, Investment Arm, Uni-Innovation Consulting Group


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-08-2023
May-25-2023
Merger/Acquisition
Target
Cyclica Therapeutics Inc
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX)
Uni-Innovation Consulting Group,Drive Capital, LLC,GreenSky Ventures
38.51
Apr-30-2020
Apr-30-2020
Private Placement
Target
Cyclica Therapeutics Inc
Drive Capital, LLC,Chiesi Farmaceutici S.p.A.,GreenSky Ventures

16.56
Sep-22-2016
Jul-26-2017
Private Placement
Target
Cyclica Therapeutics Inc
Epic Capital Management, Inc.,Uni-Innovation Consulting Group,GreenSky Ventures

4.65
Aug-11-2015
Aug-11-2015
Private Placement
Target
Cyclica Therapeutics Inc
GreenSky Ventures

-
Dec-10-2013
Dec-10-2013
Private Placement
Target
Cyclica Therapeutics Inc


0.40
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-25-2023
M&A Transaction Closings
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Cyclica Inc.
May-08-2023
M&A Transaction Announcements
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Cyclica Inc. for $40 million.
Mar-20-2023
Company Conference Presentations
Cyclica Inc. Presents at BIO-Europe Spring 2023, Mar-20-2023
Dec-13-2022
Strategic Alliances
Cyclica Inc. and SK Pharma Co., Ltd. Announces Co-Development Agreement to Co-Develop Novel Therapeutics
Oct-24-2022
Company Conference Presentations
Cyclica Inc. Presents at BIO-Europe, Oct-24-2022


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 29, 2023 02:27 AM
Cyclica Therapeutics Inc
Cyclica Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
55
GlobalData

Sep 18, 2023 03:48 AM
Cyclica Therapeutics Inc
Cyclica Inc
Reports
111
GlobalData

Sep 15, 2023 12:12 AM
Cyclica Therapeutics Inc
Cyclica Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Jun 22, 2023 02:10 AM
Cyclica Therapeutics Inc
Cyclica Inc
Reports
108
GlobalData

Jun 16, 2023 07:58 AM
Cyclica Therapeutics Inc
Cyclica Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
54
GlobalData

Jun 09, 2023 02:03 AM
Cyclica Therapeutics Inc
Cyclica Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Mar 17, 2023 04:17 AM
Cyclica Therapeutics Inc
Cyclica Inc
Reports
103
GlobalData

Mar 10, 2023 04:10 AM
Cyclica Therapeutics Inc
Cyclica Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Jan 25, 2023 03:15 AM
Cyclica Therapeutics Inc
Cyclica Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
53
GlobalData

Dec 15, 2022 01:52 AM
Cyclica Therapeutics Inc
Cyclica Inc
Reports
103


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Ligand Express Screening Platform

Key Board Members Details
Name
Title
Phone
Fax
Email
Analoui, Mostafa 
Chairman of the Board
416-304-9201
-

Kurji, Naheed 
Co-Founder, CEO, President & Director
416-304-9201
-
Naheed.Kurji@cyclicarx.com
Bonakdarpour, Molly McCartin
Director
416-304-9201
-
molly@drivecapital.com
Chilukuri, Sastry 
Director
416-304-9201
-

Conway, John F.
Scientific Advisor
416-304-9201
-

List, Michael T. R.
Director
416-585-7850 x112
-
mik@greensky.vc
Panicucci, Riccardo 
Scientific Advisor
416-304-9201
-

Prendergast, Franklyn G.
Scientific Advisor
416-304-9201
-

Wodak, Shoshana 
Scientific Advisor
416-304-9201
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Kurji, Naheed 
Co-Founder, CEO, President & Director
416-304-9201
-
Naheed.Kurji@cyclicarx.com
Shah, Pratik 
Chief Financial Officer
416-304-9201
-

McQuarrie, Holly 
Manager of People & Operations
416-304-9201
-

Palovich, Michael 
Chief Science Officer & Head of Drug Discovery
416-304-9201
-

Gotlieb, Ted 
General Counsel
416-304-9201
-

Sacco, Jennifer 
Vice President of Marketing & Communications
416-304-9201
-
jennifer.sacco@cyclicarx.com
Climie, Shane 
Vice President of Corporate Development
416-304-9201
-
sclimie@protana.com
De Biasi, Vern 
Chief Partnership Officer
416-304-9201
-

MacKinnon, Stephen 
Chief Platform Officer
416-304-9201
-

Windemuth, Andreas 
Chief Innovation Officer
416-304-9201
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
